Final Approval for Corticosteroids in Severe CAP? For Sure, in Septic Shock

Overview

Journal Crit Care

Specialty Critical Care

Date 2023 Sep 4

PMID 37667250

Authors

Ignacio Martin-Loeches

Blin Nagavci

Antoni Torres

Affiliations

Soon will be listed here.

Citing Articles

Candent issues in pneumonia. Reflections from the Fifth Annual Meeting of Spanish Experts 2023.

Rodriguez-Leal C, Gonzalez-Corralejo C, Candel F, Salavert M Rev Esp Quimioter. 2024; 37(3):221-251.

PMID: 38436606 PMC: 11094633. DOI: 10.37201/req/018.2024.

References

Vincent J . Steroids in sepsis: another swing of the pendulum in our clinical trials. Crit Care. 2008; 12(2):141. PMC: 2447597. DOI: 10.1186/cc6861. View

Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J . Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313(7):677-86. DOI: 10.1001/jama.2015.88. View

Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler J . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8(3):267-276. DOI: 10.1016/S2213-2600(19)30417-5. View

Saleem N, Kulkarni A, Snow T, Ambler G, Singer M, Arulkumaran N . Effect of Corticosteroids on Mortality and Clinical Cure in Community-Acquired Pneumonia: A Systematic Review, Meta-analysis, and Meta-regression of Randomized Control Trials. Chest. 2022; 163(3):484-497. PMC: 10808071. DOI: 10.1016/j.chest.2022.08.2229. View

Reyes L, Rodriguez A, Bastidas A, Parra-Tanoux D, Fuentes Y, Garcia-Gallo E . Dexamethasone as risk-factor for ICU-acquired respiratory tract infections in severe COVID-19. J Crit Care. 2022; 69:154014. PMC: 8863516. DOI: 10.1016/j.jcrc.2022.154014. View

Wu J, Tsai Y, Hsu W, Liu T, Huang P, Chuang M . Efficacy and safety of adjunctive corticosteroids in the treatment of severe community-acquired pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care. 2023; 27(1):274. PMC: 10329791. DOI: 10.1186/s13054-023-04561-z. View

Martin-Loeches I, Torres A, Nagavci B, Aliberti S, Antonelli M, Bassetti M . ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia. Intensive Care Med. 2023; 49(6):615-632. PMC: 10069946. DOI: 10.1007/s00134-023-07033-8. View

Dequin P, Meziani F, Quenot J, Kamel T, Ricard J, Badie J . Hydrocortisone in Severe Community-Acquired Pneumonia. N Engl J Med. 2023; 388(21):1931-1941. DOI: 10.1056/NEJMoa2215145. View

Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G . Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2004; 171(3):242-8. DOI: 10.1164/rccm.200406-808OC. View

10.

Marik P, Kraus P, Sribante J, Havlik I, Lipman J, Johnson D . Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia. A randomized controlled study. Chest. 1993; 104(2):389-92. DOI: 10.1378/chest.104.2.389. View

11.

Meduri G, Shih M, Bridges L, Martin T, El-Solh A, Seam N . Low-dose methylprednisolone treatment in critically ill patients with severe community-acquired pneumonia. Intensive Care Med. 2022; 48(8):1009-1023. PMC: 9208259. DOI: 10.1007/s00134-022-06684-3. View